Amag's shares fall after $323M pregnancy drug fails in post-approval trial

Nearly a decade after an injectable drug called Makena, now owned by Amag Pharmaceuticals Inc., became the standard of care for pregnant women at risk for preterm delivery, a new study of the drug failed to back up the company's claims that it helps reduce premature births. In a 1,700-person clinical trial, about 11 percent of women who were administered the drug by Waltham-based Amag (Nasdaq: AMAG) delivered their babies 35 weeks into their pregnancy or earlier. That was not significantly better…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news